Title: Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results from the Phase 2 Pivotal Cohort Presenter: Jorge E. Cortes, M.D. - Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results - Overview of the Phase 1b trial of R289 in patient ...

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected] Media: David Rosen Argot Partners Phone: 212.600.1902 Email:[email protected] SOUTH SAN FRANCISCO, Calif., May 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodrigue ...

SOUTH SAN FRANCISCO, Calif., May 23, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2024 Hybrid Congress. The ASCO Annual Meeting is being held online and in person in Chicago, Illinois from May 31 to June 4, 2024. The EHA2024 Congress is being held online and in per ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Farzin Haque - Jefferies Operator Greetings and we ...

Exhibit 99.1 Rigel Reports First Quarter 2024 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024, including sales of TAVALISSE (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA(olutasidenib) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Securities registered p ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Officer Dave Santos - Chief Commercial Officer Francois Di Trapani - Senior Vice President of Medical Affairs Dean Schorno - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Kristen Kluska - Cantor Fitzgerald Kalpit Patel - B. Riley ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-29889 RIGEL PHARMACEUTICALS, INC. Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary Raul Rodriguez - President & Chief Executive Officer Dean Schorno - Chief Financial Officer Dave Santos - EVP & Chief Commercial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the Third Quarter of 2023. ...

Please visit www.TAVALISSE.com for Full Prescribing Information. Please visit www.REZLIDHIA.com for Full Prescribing Information, including Boxed WARNING. Ray Furey, J.D. Dean Schorno Commercial Execution Development & Expansion • Evaluating additional olutasidenib and fostamatinib opportunities Partnered Programs 5 rigel. Select Important Safety Information 6 Please see Important Safety Information on slide 27. Please visit www.TAVALISSE.com for Full Prescribing Information. $24.5M 500 1000 1500 2000 2500 ...